MA54540A - Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations - Google Patents

Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations

Info

Publication number
MA54540A
MA54540A MA054540A MA54540A MA54540A MA 54540 A MA54540 A MA 54540A MA 054540 A MA054540 A MA 054540A MA 54540 A MA54540 A MA 54540A MA 54540 A MA54540 A MA 54540A
Authority
MA
Morocco
Prior art keywords
bispecific antibodies
bispecific
antibodies
Prior art date
Application number
MA054540A
Other languages
English (en)
French (fr)
Inventor
Aynur Hermann
Andrew J Murphy
Kara Olson
Dimitris Skokos
Eric Smith
Erica Ullman
Janelle Waite
Joyce Wei
George D Yancopoulos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA54540A publication Critical patent/MA54540A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
MA054540A 2018-12-19 2019-12-18 Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations MA54540A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862781689P 2018-12-19 2018-12-19

Publications (1)

Publication Number Publication Date
MA54540A true MA54540A (fr) 2021-10-27

Family

ID=69182681

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054540A MA54540A (fr) 2018-12-19 2019-12-18 Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations

Country Status (17)

Country Link
US (3) US11396544B2 (https=)
EP (1) EP3897715A1 (https=)
JP (2) JP7637052B2 (https=)
KR (1) KR20210104836A (https=)
CN (1) CN113164598B (https=)
AU (1) AU2019405747A1 (https=)
BR (1) BR112021010238A2 (https=)
CA (1) CA3124168A1 (https=)
CL (1) CL2021001630A1 (https=)
CO (1) CO2021009004A2 (https=)
EA (1) EA202191580A1 (https=)
IL (1) IL283945A (https=)
MA (1) MA54540A (https=)
MX (1) MX2021007497A (https=)
MY (1) MY206140A (https=)
PH (1) PH12021551401A1 (https=)
WO (1) WO2020132066A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL279354B1 (en) * 2018-06-21 2026-02-01 Regeneron Pharma Bispecific antibodies against psma and against cd28 and their uses
MA54540A (fr) 2018-12-19 2021-10-27 Regeneron Pharma Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations
CA3134335A1 (en) * 2019-03-22 2020-10-01 Regeneron Pharmaceuticals, Inc. Egfr x cd28 multispecific antibodies
CA3192204A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
MX2023003214A (es) 2020-09-18 2023-05-24 Regeneron Pharma Moleculas de union al antigeno que se unen a cd38 y/o cd28 y usos de las mismas.
AU2021374803A1 (en) * 2020-11-03 2023-06-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Target-cell restricted, costimulatory, bispecific and bivalent anti-cd28 antibodies
MX2023008081A (es) 2021-01-11 2023-09-12 Sana Biotechnology Inc Uso de vectores virales dirigidos a cd8.
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
EP4381081A1 (en) 2021-08-04 2024-06-12 Sana Biotechnology, Inc. Use of cd4-targeted viral vectors
EP4472646A1 (en) 2022-02-01 2024-12-11 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
US12365743B2 (en) 2022-02-23 2025-07-22 Xencor, Inc. Anti-CD28 x anti-PSMA antibodies
IL314916A (en) 2022-03-07 2024-10-01 Novimmune Sa Bispecific CD28 antibodies for targeted T cell activation
EP4493592A1 (en) 2022-03-14 2025-01-22 LamKap Bio gamma AG Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
CN119013295A (zh) * 2022-04-11 2024-11-22 江苏恒瑞医药股份有限公司 特异性结合egfr和cd28的抗原结合分子及其医药用途
EP4507790A1 (en) 2022-04-11 2025-02-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
CN117264065B (zh) * 2022-06-15 2025-11-18 三优生物医药(上海)有限公司 一种her2抗原结合分子及其应用
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024077268A2 (en) * 2022-10-07 2024-04-11 Fred Hutchinson Cancer Center Human metapneumovirus antibodies and uses thereof
US20240254234A1 (en) 2022-10-21 2024-08-01 Novimmune Sa PD-L1xCD28 BISPECIFIC ANTIBODIES FOR IMMUNE CHECKPOINT-DEPENDENT T CELL ACTIVATION
IL323074A (en) 2023-03-13 2025-10-01 Regeneron Pharma Methods for treating cancer with anti-CD22 x anti-CD28 bispecific molecules
CN120904324A (zh) * 2024-04-30 2025-11-07 惠和生物技术(上海)有限公司 抗cd28抗体及其用途
WO2026078067A1 (en) 2024-10-08 2026-04-16 Novimmune Sa Fcrh5 monospecific antibodies and derived fcrh5xcd28 bispecific antibodies and use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
US8496927B2 (en) 2006-09-25 2013-07-30 National University Corporation Nagoya University CD20 negatively converted B-cell malignant lymphoma cell line and utilization thereof
US20130079353A1 (en) 2009-12-22 2013-03-28 Karsten Gülow Fluoroquinolones for the treatment and/or prophylaxis of inflammatory diseases
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
WO2012171020A1 (en) * 2011-06-10 2012-12-13 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
CA2861491C (en) * 2012-02-13 2020-08-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
WO2014044793A2 (en) 2012-09-20 2014-03-27 Max-Delbrück-Centrum für Molekulare Medizin Cd22-binding peptides
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
AU2016325630B2 (en) 2015-09-23 2022-11-17 Regeneron Pharmaceuticals, Inc. Optimized anti-CD3 bispecific antibodies and uses thereof
JP7066690B2 (ja) 2016-09-23 2022-05-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｍｕｃ１６（ムチン１６）抗体
MY199468A (en) 2016-09-23 2023-10-31 Regeneron Pharma Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
JP7784795B2 (ja) 2016-11-15 2025-12-12 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与
CN113286811B (zh) * 2018-07-30 2024-12-06 南加利福尼亚大学 改善过继性细胞疗法的效力和安全性
CN109021114B (zh) * 2018-08-08 2020-06-09 武汉波睿达生物科技有限公司 联合两种单链抗体的双特异性嵌合抗原受体及表达载体
MA54540A (fr) * 2018-12-19 2021-10-27 Regeneron Pharma Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations

Also Published As

Publication number Publication date
WO2020132066A8 (en) 2020-07-30
US20200239576A1 (en) 2020-07-30
CN113164598A (zh) 2021-07-23
WO2020132066A1 (en) 2020-06-25
US20230174652A1 (en) 2023-06-08
JP7637052B2 (ja) 2025-02-27
BR112021010238A2 (pt) 2021-08-24
IL283945A (en) 2021-07-29
EA202191580A1 (ru) 2021-11-01
MY206140A (en) 2024-11-30
AU2019405747A1 (en) 2021-06-17
CL2021001630A1 (es) 2021-12-17
JP2022510964A (ja) 2022-01-28
PH12021551401A1 (en) 2022-05-11
CO2021009004A2 (es) 2021-07-30
MX2021007497A (es) 2021-08-05
US20250223360A1 (en) 2025-07-10
KR20210104836A (ko) 2021-08-25
JP2025013425A (ja) 2025-01-24
EP3897715A1 (en) 2021-10-27
CN113164598B (zh) 2025-04-25
US11396544B2 (en) 2022-07-26
CA3124168A1 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
MA54540A (fr) Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations
FR25C1029I2 (fr) Anticorps anti-bcma x anti-cd3 bispécifiques et leurs utilisations
MA54539A (fr) Anticorps anti-muc16 x anti-cd28 bispécifiques et leurs utilisations
MA52970A (fr) Anticorps anti-psma x anti-cd28 bispécifiques et leurs utilisations
MA52771A (fr) Anticorps anti-cd33, anticorps bispécifiques anti-cd33/anti-cd3 et leurs utilisations
EP3891187A4 (en) ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF
MA52773A (fr) Anticorps anti-cd3 et leurs utilisations
EP3891183A4 (en) ANTI-CLAUDIN ANTIBODIES AND USES THEREOF
MA52949A (fr) Anticorps anti-pd-1 et leurs utilisations
EP3833693A4 (en) ANTI-PD-L1/ANTI-LAG3 BISPECIFIC ANTIBODIES AND USES THEREOF
EP3897719A4 (en) Protease cleavable bispecific antibodies and uses thereof
EP3759143A4 (en) ANTI-TIGIT ANTIBODIES AND USES THEREOF
EP3898691A4 (en) TREM2 ANTIBODIES AND USES THEREOF
MA52414A (fr) Anticorps agonistes de pd-1 et leurs utilisations
EP3625263A4 (en) ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF
EP3621642A4 (en) HUMAN MONOCLONAL ANTIBODIES AGAINST LAG3 AND USES THEREOF
MA42935A (fr) Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations
MA46708A (fr) Anticorps anti-pd1 et leurs utilisations
EP3661555A4 (en) SPECIFIC ANTIBODIES AND USES THEREOF
EP3790586A4 (en) ANTI-DLL3 ANTIBODIES AND USES THEREOF
EP3645563A4 (en) ANTI-FAM19A5 ANTIBODIES AND USES THEREOF
EP3966252A4 (en) HUMANIZED ANTI-CD137 ANTIBODIES AND USES THEREOF
EP3755716A4 (en) ANTI-PD-1 ANTIBODIES AND USES THEREOF
EP3850012A4 (en) Anti-tnfrsf9 antibodies and uses thereof
EP3883969A4 (en) ANTI-PD-1 ANTIBODIES AND USES THEREOF